Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KADCYLA vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
Adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment,Treatment of patients with HER2-positive metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination,Off-label: Use in HER2-positive advanced gastric cancer (limited data)
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
Terminal half-life approximately 4 days (range 2.8-5.6 days), supporting every-3-week dosing.
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
DM1 is primarily metabolized by CYP3A4 and to a lesser extent by CYP3A5.
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Primarily hepatic metabolism with biliary excretion; minimal renal elimination (<10% unchanged).
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
93% bound to plasma proteins (trastuzumab component).
47% bound to human plasma proteins, primarily albumin.
Approximately 2.58 L/m² (central Vd), indicating limited extravascular distribution.
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
100% (intravenous administration only).
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Safety and efficacy not established in severe renal impairment (Cr Cl <30 m L/min).
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
No dose adjustment for mild hepatic impairment (Child-Pugh A). Not recommended for moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment due to lack of data.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Safety and efficacy in pediatric patients have not been established.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
No specific dose adjustment recommended for elderly patients. Clinical studies included patients aged ≥65 years, but no overall differences in safety or efficacy were observed.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
WARNING: HEPATOTOXICITY, CARDIAC TOXICITY, EMBRYO-FETAL TOXICITY Hepatotoxicity: Severe hepatotoxicity has been observed, including liver failure and death. Monitor liver function tests prior to each dose and as clinically indicated. Cardiac Toxicity: Left ventricular ejection fraction (LVEF) should be assessed prior to initiation and at regular intervals during treatment. Discontinue for clinically significant decline. Embryo-Fetal Toxicity: Exposure during pregnancy can cause embryo-fetal harm. Advise patients of these risks and need for effective contraception.
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
Hepatotoxicity: Monitor liver function tests; dose reduction or discontinuation may be required for elevated liver enzymes or bilirubin.,Cardiac toxicity: Assess LVEF before and during treatment; discontinue if symptomatic heart failure or significant asymptomatic decline.,Pulmonary toxicity: Interstitial lung disease (ILD) including pneumonitis has been reported; monitor for signs/symptoms and discontinue if confirmed.,Extravasation: Administer as IV infusion; extravasation may cause tissue necrosis. Ensure proper IV access.,Thrombocytopenia: Monitor platelet counts; dose modifications required for grade 3 or 4 thrombocytopenia.,Neuropathy: Peripheral neuropathy may occur; monitor and manage accordingly.,Embryo-fetal toxicity: Advise of risk and use effective contraception during and 7 months after treatment.,Increased intracranial pressure: Cases of reversible posterior leukoencephalopathy syndrome (RPLS) reported; monitor and discontinue if occurs.
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
Known hypersensitivity to ado-trastuzumab emtansine or any of its components,Pregnancy (can cause embryo-fetal harm)
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
No specific food interactions are known for Kadcyla. However, avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 and potentially increase exposure. Maintain a healthy diet to manage nausea and support overall health.
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
Kadcyla (ado-trastuzumab emtansine) is an antibody-drug conjugate. Trastuzumab component can cause oligohydramnios, fetal renal impairment, and pulmonary hypoplasia when administered during the second and third trimesters. The DM1 component (emtansine) is a microtubule inhibitor with potential embryofetal toxicity. Based on its mechanism and animal studies, there is risk for teratogenicity in the first trimester, including structural anomalies. Avoid use during pregnancy unless benefit outweighs risk; advise effective contraception.
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
It is not known whether Kadcyla is excreted in human milk. Due to the potential for serious adverse reactions in nursing infants, including tumorigenicity and developmental toxicity, advise women not to breastfeed during treatment and for at least 7 months after the last dose. M/P ratio is unknown.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
No dose adjustment recommendations specific to pregnancy; however, pharmacokinetics may be altered due to increased plasma volume and renal clearance. Use only if clearly needed. Consider therapeutic drug monitoring if available, but no established target levels. Close maternal-fetal monitoring recommended.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
Monitor left ventricular ejection fraction (LVEF) before and during treatment due to risk of cardiotoxicity. Infusion reactions are common; premedicate with antihistamines and corticosteroids. Do not substitute trastuzumab emtansine for trastuzumab or ado-trastuzumab emtansine. Avoid concomitant use with strong CYP3A4 inhibitors or inducers. Monitor for hepatotoxicity and pulmonary toxicity. Dose reduction required for thrombocytopenia or elevated transaminases.
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
This drug is given as an IV infusion every 3 weeks. It may cause infusion reactions during or shortly after administration; tell your doctor immediately if you experience chills, fever, difficulty breathing, or chest pain.,Kadcyla can cause heart problems; you will have regular heart function tests (echocardiograms) before and during treatment. Report any new shortness of breath, cough, or swelling of ankles/legs.,This medication can cause liver damage; blood tests will be done to monitor liver function. Notify your doctor if you develop yellowing of skin/eyes, dark urine, or abdominal pain.,Kadcyla may lower platelet counts, increasing bleeding risk. Avoid activities that may cause injury or bruising. Report unusual bleeding or bruising.,This drug can cause severe birth defects; use effective contraception during treatment and for at least 7 months after the last dose. Do not breastfeed while taking Kadcyla.,You may experience fatigue, nausea, muscle/joint pain, or headache. Report persistent or severe symptoms to your healthcare provider.
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KADCYLA vs CLOLAR, answered by our medical review team.
KADCYLA is a Antineoplastic Agent that works by KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KADCYLA and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KADCYLA is: 3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KADCYLA and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KADCYLA is classified as Category C. Kadcyla (ado-trastuzumab emtansine) is an antibody-drug conjugate. Trastuzumab component can cause oligohydramnios, fetal renal impairment, and pulmonary hypoplasia when administer. CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.